

I hereby certify that this correspondence is being facsimile  
transmitted to the United States Patent and Trademark Office,  
Fax No. 1-703-872-9306

PATENT  
Attorney Docket No.: 15270J-00S912US  
Client Ref. No.: 209-US-NEW6C2

TOWNSEND and TOWNSEND and CREW LLP

By: 

Rosemarie L. Celli

#8  
BQJ  
9/28/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/724,575

Filed: November 28, 2000

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Sharon L. Turner

Art Unit: 1647

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicant files this response to the Restriction Requirement mailed March 27, 2002. A petition to extend the time of response from April 27, 2002 to September 27, 2002 is transmitted herewith. The paragraph numbering of the Restriction Requirement is used in responding to the Examiner's remarks.

¶¶1-8 Applicant elects Group II, claims 11-25.

¶¶9-10 Applicant traverses the Restriction Requirement, and provisionally elects transthyretin of claim 13, and the ATTR fragment of claim 15. Applicant acknowledges the Examiner's requirement to elect a single amyloid component, i.e., Applicant must elect one amyloid component, agent, and fibril component from each of claims 13, and 15 of elected Group II. Applicant respectfully points out that claim 13 recites precursor proteins and not and not amyloid components. Applicant's provisional election of transthyretin is based on the assumption that the Examiner intended to require that Applicant elect a precursor proteins, not an amyloid component, from claim 13.

Dale B. Schenk  
Application No.: 09/724,575  
Page 2

PATENT

The Examiner has effectively required restriction between 17 species of generic claim 13, *i.e.*, Serum Amyloid A protein (ApoSSA), immunoglobulin light chain, immunoglobulin heavy chain, ApoAI, transthyretin, lysozyme, fibrogen  $\alpha$  chain, gelsolin, cystatin C, Amyloid  $\beta$  protein precursor ( $\beta$ -APP), Beta<sub>2</sub> microglobulin, prion precursor protein (PrP), atrial natriuretic factor, keratin, islet amyloid polypeptide, a peptide hormone, and synuclein, including mutant proteins, protein fragments or peptides thereof. The Examiner has also effectively required restriction between 13 species of generic claim 15, *i.e.*, AA, AL, ATTR, AapoA1, Alys, Agel, Acys, A $\beta$ , AB<sub>2</sub>M, AScr, Acal, AIAPP and synuclein-NAC fragment.

The Examiner maintains that this requirement is not to be construed as a requirement for an election of species, since each of the compounds recited in alternative form is not a member of a single genus of invention, but constitutes an independent and patentably distinct invention. The only justification or statutory authority put forth by the Restriction Requirement for refusing to examine claim 13 is 35 U.S.C. § 121. However, there is nothing therein to excuse a refusal to examine an elected invention or a generic claim reading thereon.

As a preliminary matter, alleging that a particular claim represents multiple patentably distinct inventions is a *de facto* rejection of the patentability of the claim, because the claim cannot issue as drafted. As the C.C.P.A. noted:

As a general proposition, an applicant has a right to have each claim examined on the merits. If an applicant submits a number of claims, it may well be that pursuant to a proper restriction requirement, those claims will be dispersed to a number of applications. Such action would not affect the rights of the applicant eventually to have each of the claims examined in the form he considers best define his invention. If, however, a single claim is required to be divided up and presented in several applications, that claim would never be considered on the merits. The totality of the resulting fragmentary claims would not necessarily be the equivalent of the original claim. Further, since the subgenera would be defined by the examiner, rather than by the applicant, it is not inconceivable that a number of the fragments would not be described in the specification.

Dale B. Schenk  
Application No.: 09/724,575  
Page 3

PATENT

*See, In Re Weber, Soder and Boksay* 198 USPQ 328, 331 (C.C.P.A. 1978). *See also, In Re Haas* 179 USPQ 623, 624, 625 (*In Re Haas I*) (C.C.P.A. 1973) and *In Re Haas* 198 USPQ 334-337 (*In Re Haas II*) (C.C.P.A. 1978).

Moreover, it has been held that an Examiner may not reject a particular claim on the basis that it represents independent and distinct inventions. *See, In Re Weber, Soder and Boksay, Supra*. The courts have ruled that the statute authorizing restriction practice, i.e., 35 U.S.C. § 121, provides no legal authority to impose a restriction requirement on a single claim, even if the claim presents multiple independently patentable inventions. *See, In Re Weber, Soder and Boksay, In Re Haas I and In Re Haas II*. In the cases set forth above, the courts expressly ruled that there is no statutory basis for rejecting a claim for misjoinder, despite previous attempts by the Patent Office to fashion such a rejection. As noted in *In Re Weber, Soder and Boksay*:

The discretionary power to limit one applicant to one invention is no excuse at all for refusing to examine a broad generic claim-- no matter how broad, which means no matter how many independently patentable inventions may fall within it.

*See, In Re Weber, Soder and Boksay* at 334.


Instead of imposing a restriction requirement on a single claim, the Office may limit initial examination to a reasonable number of species encompassed by the claim. *See, 37 C.F.R. § 1.146*. This practice strikes an appropriate balance between the concerns of the patent office regarding administrative concerns and unduly burdensome examination, and the clear constitutional and statutory rights of an inventor to claim an invention as it is contemplated, provided the dictates of 35 U.S.C. § 112 are complied with. *See, the MPEP at 803.02. See also, In Re Wolfrum* 179 USPQ 620 (C.C.P.A. 1973) and *In re Kuehl* 177 U.S.P.Q. 250 (C.C.P.A. 1973). Unlike a restriction requirement, a species election does not preclude an applicant from pursuing the original form of a claim in subsequent prosecution, nor does it force an applicant to file multiple divisional applications which are incapable of capturing the intended scope of the application.

Dale B. Schenk  
Application No.: 09/724,575  
Page 4

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

  
Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: (650) 326-2422  
RLC:lah  
PA 3251680 v1